Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Acquires Teva Group API Maker Watson

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Growth Story
Zydus Is Planning For Growth, But Will Generic Revlimid Cast A Shadow • Source: Shutterstock

Zydus Lifesciences Limited expects gains from a second quarter launch of a generic to Bristol Myers Squibb Company’s blockbuster oncology drug Revlimid (lenalidomide) to extend beyond the fourth quarter of FY23, which ends 31 March next year.

Multiple Indian companies either have launched or have plans to launch gRevlimid. The first mover Natco Pharma Limited had seen Q1 revenues grow by a whopping 116% year-on-year on the back of gRevlimid, which was launched post a limited volume settlement with the originator

Similarly, Dr. Reddy's Laboratories Ltd.’s which had 180-day exclusivity for lenalidomide capsules in the 2

More from Business

More from Scrip